Jung ST - Search Results

1

Engineering therapeutic antibodies targeting G-protein-coupled receptors.

Jo M, Jung ST. Jo M, et al. Among authors: jung st. Exp Mol Med. 2016 Feb 5;48(2):e207. doi: 10.1038/emm.2015.105. Exp Mol Med. 2016. PMID: 26846450 Free PMC article. Review.

2

Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance.

Jo M, Kwon HS, Lee KH, Lee JC, Jung ST. Jo M, et al. Among authors: jung st. MAbs. 2018 Feb/Mar;10(2):278-289. doi: 10.1080/19420862.2017.1402995. Epub 2017 Dec 7. MAbs. 2018. PMID: 29173039 Free PMC article.

3

Engineered human FcγRIIa fusion: A novel strategy to extend serum half-life of therapeutic proteins.

Jo M, Ko S, Hwang B, Min SW, Ha JY, Lee JC, Jang SE, Jung ST. Jo M, et al. Among authors: jung st. Biotechnol Bioeng. 2020 Aug;117(8):2351-2361. doi: 10.1002/bit.27374. Epub 2020 May 16. Biotechnol Bioeng. 2020. PMID: 32369186

4

Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies.

Ju MS, Jung ST. Ju MS, et al. Among authors: jung st. Int J Mol Sci. 2020 Nov 3;21(21):8240. doi: 10.3390/ijms21218240. Int J Mol Sci. 2020. PMID: 33153215 Free PMC article. Review.

5

Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering.

Ko S, Jo M, Jung ST. Ko S, et al. Among authors: jung st. BioDrugs. 2021 Mar;35(2):147-157. doi: 10.1007/s40259-021-00471-0. Epub 2021 Feb 19. BioDrugs. 2021. PMID: 33608823 Free PMC article. Review.

6

A human antibody against human endothelin receptor type A that exhibits antitumor potency.

Ju MS, Ahn HM, Han SG, Ko S, Na JH, Jo M, Lim CS, Ko BJ, Yu YG, Lee WK, Kim YJ, Jung ST. Ju MS, et al. Among authors: jung st. Exp Mol Med. 2021 Sep;53(9):1437-1448. doi: 10.1038/s12276-021-00678-9. Epub 2021 Sep 29. Exp Mol Med. 2021. PMID: 34588605 Free PMC article.

7

An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies.

Ko S, Park S, Sohn MH, Jo M, Ko BJ, Na JH, Yoo H, Jeong AL, Ha K, Woo JR, Lim C, Shin JH, Lee D, Choi SY, Jung ST. Ko S, et al. Among authors: jung st. Exp Mol Med. 2022 Nov;54(11):1850-1861. doi: 10.1038/s12276-022-00870-5. Epub 2022 Nov 1. Exp Mol Med. 2022. PMID: 36319752 Free PMC article.

8

Engineered Human Antibody with Improved Endothelin Receptor Type A Binding Affinity, Developability, and Serum Persistence Exhibits Excellent Antitumor Potency.

Ko S, Ju MS, Ahn HM, Na JH, Ko WH, Jo M, Kyung M, Lim CS, Ko BJ, Lee WK, Kim YJ, Jung ST. Ko S, et al. Among authors: jung st. Mol Pharm. 2023 Feb 6;20(2):1247-1255. doi: 10.1021/acs.molpharmaceut.2c00923. Epub 2022 Dec 23. Mol Pharm. 2023. PMID: 36563318

9

Unlocking the Power of Complement-Dependent Cytotoxicity: Engineering Strategies for the Development of Potent Therapeutic Antibodies for Cancer Treatments.

Lee W, Lee SM, Jung ST. Lee W, et al. Among authors: jung st. BioDrugs. 2023 Sep;37(5):637-648. doi: 10.1007/s40259-023-00618-1. Epub 2023 Jul 24. BioDrugs. 2023. PMID: 37486566 Review.

10

Detection and purification of backbone-cyclized proteins using a bacterially expressed anti-myc-tag single chain antibody.

Chauhan S, Hou CY, Jung ST, Kang TJ. Chauhan S, et al. Among authors: jung st. Anal Biochem. 2017 Sep 1;532:38-44. doi: 10.1016/j.ab.2017.06.003. Epub 2017 Jun 7. Anal Biochem. 2017. PMID: 28600127

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters